| 32.93 Data as of May 17 |  -0.20 / -0.60%Today’s Change | 22.02 Today|||52-Week Range 34.70 | +20.84% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $2.6B |
Company Description
Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing novel predictive and personalized medicines and prognostic medicine products. The company operates through three reportable segments: Research, Molecular Diagnostics and Companion Diagnostics. The Research segment focuses on the discovery of genes related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The Molecular Diagnostics segment provides testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The Companion Diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. Myriad Genetics was founded in May 1991 and is headquartered in Salt Lake City, UT.
Employees
Shareholders
| Mutual fund holders | 51.01% |
| Other institutional | 44.43% |
| Individual stakeholders | 2.03% |
Top Executives
| Peter D. Meldrum | President, Chief Executive Officer & Director |
| Gary A. King, MBA | Executive Vice President-International Operations |
| James S. Evans, CPA | Chief Financial Officer & Treasurer |
| Robert Gardner Harrison | Chief Information Officer |
| Jerry S. Lanchbury, PhD | Chief Scientific Officer |
.
